MediWound Ltd. (MDWD) Balance Sheet

The rapid fluctuation in total assets and equity suggests that the company is struggling to maintain a stable capital base while navigating the high costs of clinical development. Investors should monitor whether the recent asset expansion is sustainable or merely a temporary artifact of financing activities that do not address the underlying lack of commercial scale.

The current ratio of 2.33 in 2025Q4 provides a misleading sense of security, as the absolute cash balance is insufficient to cover the company's historical quarterly burn rate. This liquidity profile suggests that the firm may be forced into dilutive financing rounds or emergency capital measures if commercial adoption of NexoBrid does not accelerate immediately.

The concentration of assets in PPE relative to total assets suggests an asset-heavy business model that requires significant throughput to achieve break-even. The lack of meaningful goodwill or intangible assets indicates that the company's value is tied almost exclusively to its physical production capabilities and clinical pipeline, which remain unproven at scale.

While the low leverage ratio appears conservative, it likely reflects limited access to credit markets rather than a strategic choice to avoid debt. The company's reliance on equity-linked financing or government support appears to be the primary mechanism for funding, which warrants caution regarding future shareholder dilution.